Biopharma Daily Stock Updates - 03/23/21

$XBI $138.54 -6%

Covid Updates

$OMER -1% Dosing of patients with narsoplimab for covid-19 started earlier this month. source


$AZN -3% Update on validating covid-19 data announced yesterday. source


Pipeline Updates

$ORMP +5% Initiates ph 3 oral insulin study under FDA approved protocol. source


$PGEN -6% Fist patient dosed for PRGN-2012 in recurrent respiratory papillomatosis (RRP). source


$LCTX -1% Interim results from ongoing ph 1/2a study of OpRegen. source


$AKRO -4% First patient randomized for dosing in ph 2b study of efruxifermin in NASH. source


$VTVT 6% Patent 10,952,993 issued for TTP399. source


$ASND -4% Data from 6-mo open-label ph 2 study of TransCon. source


$FREQ -78% Topline data from ph 2a study for FX-322. source


$IDYA -2% Dose expansion in ph 1/2 study of IDE196 and binimetinib. source


Financial Updates

$PRTA -12% Public offering. source


$XOMA -4% purchased future milestones and royalties associated with licenses for DAY101 and vosaroxin. source

0 comments